[go: up one dir, main page]

MX2023008423A - Anticuerpos anti-gremlin1 novedosos. - Google Patents

Anticuerpos anti-gremlin1 novedosos.

Info

Publication number
MX2023008423A
MX2023008423A MX2023008423A MX2023008423A MX2023008423A MX 2023008423 A MX2023008423 A MX 2023008423A MX 2023008423 A MX2023008423 A MX 2023008423A MX 2023008423 A MX2023008423 A MX 2023008423A MX 2023008423 A MX2023008423 A MX 2023008423A
Authority
MX
Mexico
Prior art keywords
gremlin1
antibodies
novel anti
same
antigen
Prior art date
Application number
MX2023008423A
Other languages
English (en)
Inventor
Xueming Qian
Hongjun Li
Huanhuan Guo
Suli Cui
Di Sun
Original Assignee
Suzhou Transcenta Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Transcenta Therapeutics Co Ltd filed Critical Suzhou Transcenta Therapeutics Co Ltd
Publication of MX2023008423A publication Critical patent/MX2023008423A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente divulgación proporciona anticuerpos anti-gremlin1 o fragmentos de unión a antígeno de los mismos, polinucleótidos aislados que codifican los mismos, composiciones farmacéuticas que comprenden los mismos y los usos de los mismos.
MX2023008423A 2021-01-18 2022-01-17 Anticuerpos anti-gremlin1 novedosos. MX2023008423A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021072397 2021-01-18
CN2021142043 2021-12-28
PCT/CN2022/072297 WO2022152290A1 (en) 2021-01-18 2022-01-17 Novel anti-gremlin1 antibodies

Publications (1)

Publication Number Publication Date
MX2023008423A true MX2023008423A (es) 2023-07-26

Family

ID=82446960

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008423A MX2023008423A (es) 2021-01-18 2022-01-17 Anticuerpos anti-gremlin1 novedosos.

Country Status (10)

Country Link
US (1) US20240294622A1 (es)
EP (1) EP4277927A4 (es)
JP (1) JP2024504124A (es)
KR (1) KR20230132544A (es)
CN (1) CN116848135A (es)
AU (1) AU2022207030A1 (es)
CA (1) CA3208455A1 (es)
MX (1) MX2023008423A (es)
TW (1) TW202241944A (es)
WO (1) WO2022152290A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022233762A1 (en) * 2021-03-11 2023-10-05 Shanghai Jiao Tong University Method of treating diseases using gremlin1 antagonists
GB202205203D0 (en) * 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
GB202205200D0 (en) * 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
WO2024213066A1 (en) * 2023-04-13 2024-10-17 Suzhou Transcenta Therapeutics Co., Ltd. Combination therapies involving grem1 antagonists for treatment of cancer
WO2025148900A1 (en) * 2024-01-08 2025-07-17 Suzhou Transcenta Therapeutics Co., Ltd. Combination therapy of grem1 antagonist and activin receptor antagonist for treating pah
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6339063B2 (ja) * 2012-03-15 2018-06-06 エスエヌユー アールアンドディービー ファウンデーション グレムリン−１に対する抗体
EA201591762A1 (ru) * 2013-03-14 2015-12-30 Ридженерон Фармасьютикалз, Инк. Человеческие антитела к grem1
AU2017320989A1 (en) * 2016-08-29 2019-02-07 Regeneron Pharmaceuticals, Inc. Anti-gremlin-1 (GREM1) antibodies and methods of use thereof for treating pulmonary arterial hypertension
GB201621635D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
US12162934B2 (en) * 2018-06-18 2024-12-10 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer
AU2022233762A1 (en) * 2021-03-11 2023-10-05 Shanghai Jiao Tong University Method of treating diseases using gremlin1 antagonists

Also Published As

Publication number Publication date
EP4277927A1 (en) 2023-11-22
AU2022207030A1 (en) 2023-08-24
CA3208455A1 (en) 2022-07-21
EP4277927A4 (en) 2025-07-23
JP2024504124A (ja) 2024-01-30
US20240294622A1 (en) 2024-09-05
CN116848135A (zh) 2023-10-03
WO2022152290A1 (en) 2022-07-21
KR20230132544A (ko) 2023-09-15
AU2022207030A9 (en) 2024-09-19
TW202241944A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
CA3149406A1 (en) Novel anti-cldn18.2 antibodies
MX2022007959A (es) Nuevos anticuerpos anti-fgfr2b.
MX2024007966A (es) Anticuerpos anti-tslp novedosos.
MX2022007961A (es) Nuevos anticuerpos anti-fgfr2b.
MX2023008423A (es) Anticuerpos anti-gremlin1 novedosos.
WO2021183839A3 (en) Novel anti-lilrb4 antibodies and derivative products
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
WO2020039321A3 (en) Anti-gdf15 antibodies, compositions and methods of use
MX2025009320A (es) Anticuerpos anti-cd19 novedosos
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12020550078A1 (en) Novel anti-cd3epsilon antibodies
EP3957723A3 (en) Engineered ligase variants
MX2022007960A (es) Nuevos anticuerpos anti-fgfr2b.
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
WO2017106684A3 (en) Antibodies specifically binding hla-dr and their uses
ZA202309516B (en) Anti-ccr8 antibodies
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
WO2020260898A3 (en) Novel cancer antigens and methods
EP4273165A3 (en) Interferon beta antibodies and uses thereof
WO2021207948A9 (en) Anti-sars-cov-2 antibodies and uses thereof
MX2024011805A (es) Nuevos anticuerpos anti-fgfr2
WO2020073835A8 (zh) 白介素-6的人源化单克隆抗体、其编码基因及应用
MX2020010092A (es) Variantes de anticuerpo c-terminales.